Comorbidity thyrotoxicosis with coronary heart disease

Аннотация

Objective: to evaluate the effect of thyrostatics on clinical symptoms, the frequency of cardiac arrhythmias and morpho-functional parameters of the left heart in patients with a combination of thyrotoxicosis and ischemic heart failure. Materials and methods: 51 patients participated in the study. Group I — patients with CHF of functional class II–III (FC) on the background of coronary heart disease and concomitant thyrotoxicosis (n=24), average age — 58.6±4.6 years; group II — patients with manifest thyrotoxicosis without cardiovascular pathology (n=27), average age — 46.7±4.1 years. When included in the study and after 6 months of therapy with the addition of thyrostatics, the clinical condition of patients and physical activity were evaluated, daily monitoring of an electrocardiogram and an echocardiographic study (EchoCG) were performed.